tiprankstipranks
Trending News
More News >
Grand Pharmaceutical Group Limited (HK:0512)
:0512
Hong Kong Market
Advertisement

Grand Pharmaceutical Group Limited (0512) AI Stock Analysis

Compare
4 Followers

Top Page

HK:0512

Grand Pharmaceutical Group Limited

(0512)

Rating:67Neutral
Price Target:
HK$9.00
▼(-4.26% Downside)
The overall stock score reflects strong financial performance, with robust revenue growth and stable cash flow generation. However, technical analysis indicates bearish momentum, which is a significant concern. The valuation is reasonable, with an attractive dividend yield. Addressing the EBIT margin decline and improving market momentum could enhance the stock's attractiveness.

Grand Pharmaceutical Group Limited (0512) vs. iShares MSCI Hong Kong ETF (EWH)

Grand Pharmaceutical Group Limited Business Overview & Revenue Model

Company DescriptionGrand Pharmaceutical Group Limited (0512) is a prominent player in the pharmaceutical industry, primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates in various sectors, including prescription drugs, over-the-counter medications, and medical devices. Its core products and services cater to a wide range of therapeutic areas, offering innovative solutions to enhance health and wellness.
How the Company Makes MoneyGrand Pharmaceutical Group Limited generates revenue through multiple streams, primarily through the sale of its pharmaceutical products and medical devices. The company leverages its robust research and development capabilities to bring novel and effective medications to market, targeting both domestic and international markets. Revenue is also derived from strategic partnerships with other pharmaceutical companies, licensing agreements, and distribution deals, which help expand the reach of its products. Additionally, the company invests in marketing and sales initiatives to boost the uptake of its products in various healthcare settings. These factors collectively contribute to its financial performance and growth.

Grand Pharmaceutical Group Limited Financial Statement Overview

Summary
Grand Pharmaceutical Group Limited shows strong revenue growth and profitability, with a robust gross profit margin. However, the EBIT margin has declined to 0%, which is a concern. The balance sheet is stable with prudent debt management, and cash flow generation remains strong, supporting operations and growth initiatives.
Income Statement
85
Very Positive
Grand Pharmaceutical Group Limited has demonstrated strong revenue growth with a CAGR of approximately 12% over the past five years. The gross profit margin remains robust, exceeding 50% consistently. However, the EBIT margin declined to 0% in the latest year, which is a concern. Nevertheless, the EBITDA margin is satisfactory, indicating strong operational efficiency.
Balance Sheet
78
Positive
The company maintains a solid equity position with an equity ratio of 65.9% for 2024. The debt-to-equity ratio is manageable at 27%, showing prudent leverage. Return on equity remains healthy, although slightly declining, reflecting consistent profitability. Overall, the balance sheet reflects stability with room for improvement in asset utilization.
Cash Flow
82
Very Positive
Operating cash flow is positive and supports net income, with a stable operating cash flow to net income ratio. Free cash flow decreased by 33.8% from the previous year, largely due to increased capital expenditure. Despite this, cash flow generation remains strong, providing a cushion for strategic investments and debt servicing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.64B10.53B9.56B8.60B6.35B
Gross Profit6.74B6.52B5.95B5.25B4.04B
EBITDA3.39B2.97B3.09B3.10B2.41B
Net Income2.47B1.88B2.08B2.40B1.79B
Balance Sheet
Total Assets24.99B22.52B22.37B21.06B16.98B
Cash, Cash Equivalents and Short-Term Investments3.14B2.47B2.48B2.87B2.39B
Total Debt4.44B3.40B4.48B3.65B2.39B
Total Liabilities8.47B7.24B8.16B7.61B5.64B
Stockholders Equity16.47B15.16B14.14B13.39B11.24B
Cash Flow
Free Cash Flow1.28B1.93B245.79M1.49B1.31B
Operating Cash Flow1.90B2.42B1.92B2.12B1.78B
Investing Cash Flow-2.00B-515.75M-2.58B-2.05B-2.05B
Financing Cash Flow29.96M-1.89B464.49M-195.08M899.79M

Grand Pharmaceutical Group Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.40
Price Trends
50DMA
8.99
Positive
100DMA
8.30
Positive
200DMA
6.49
Positive
Market Momentum
MACD
0.16
Negative
RSI
57.83
Neutral
STOCH
62.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0512, the sentiment is Positive. The current price of 9.4 is above the 20-day moving average (MA) of 8.77, above the 50-day MA of 8.99, and above the 200-day MA of 6.49, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 57.83 is Neutral, neither overbought nor oversold. The STOCH value of 62.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0512.

Grand Pharmaceutical Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
HK$33.37B15.8312.65%2.77%10.56%-13.58%
51
Neutral
$7.84B-0.18-41.53%2.28%22.72%-1.87%
£2.00B5.3848.58%
$3.88B7.0321.02%3.77%
$4.09B14.3510.01%2.78%
$4.78B13.6215.72%3.94%
€3.36B9.235.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0512
Grand Pharmaceutical Group Limited
9.40
5.19
123.28%
GB:HCM
HUTCHMED (China)
222.00
-44.00
-16.54%
ULIHF
The United Laboratories International Holdings
1.64
0.52
46.43%
CHSYF
China Medical System Holdings
1.35
0.47
53.41%
LVZPF
Livzon Pharmaceutical Group
4.55
1.51
49.67%
DE:640
China Resources Pharmaceutical Group Ltd.
0.52
-0.08
-13.33%

Grand Pharmaceutical Group Limited Corporate Events

Grand Pharmaceutical Group Schedules Board Meeting for Interim Results
Aug 5, 2025

Grand Pharmaceutical Group Limited has announced that its board of directors will hold a meeting on August 19, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.

Grand Pharmaceutical Restructures Shareholding, Increases Stake
Jul 28, 2025

Grand Pharmaceutical Group Limited announced a restructuring of its shareholding, with Outwit Investments Limited acquiring additional shares from East Ocean Capital, increasing its stake to 53.42% of the company’s total issued share capital. This internal restructuring, involving entities ultimately controlled by Beijing Huachuang, does not change the ultimate control of the company, and a waiver was obtained to avoid a general offer under the Hong Kong Code on Takeovers and Mergers.

Grand Pharmaceutical’s TLX591 Gains Approval for International Phase III Trial
Jul 22, 2025

Grand Pharmaceutical Group Limited has announced that its investigational radionuclide-drug conjugate, TLX591, for treating prostate cancer has received implied approval from China’s National Medical Products Administration to join an international Phase III clinical trial. This trial, involving over 500 patients across multiple countries, aims to evaluate the efficacy and safety of TLX591 in combination with standard care. The product, developed in collaboration with Telix Pharmaceuticals, offers a shorter treatment cycle and improved safety profile compared to existing therapies, potentially redefining the treatment standard for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Grand Pharmaceutical and Sirtex Group Collaborate on Radiopaque Product Development
Jul 17, 2025

Grand Pharmaceutical Group Limited has entered into a Business Collaboration Agreement with the Sirtex Group to jointly develop new radiopaque pharmaceutical products. This collaboration aims to leverage both companies’ expertise and resources, potentially enhancing their global presence and market opportunities by sharing R&D capabilities, resources, and technical knowledge.

Grand Pharmaceutical Launches Innovative Dry Eye Nasal Spray in China
Jul 17, 2025

Grand Pharmaceutical Group Limited announced the first commercial prescription of its nasal spray product, OC-01, for treating dry eye disease in Mainland China. This product, which is the first of its kind globally, offers a new treatment option for dry eye patients by increasing tear secretion through a nasal spray, potentially improving patient compliance compared to traditional eye drops. The company views ophthalmology as a strategic development area and aims to strengthen its market position with innovative products and a robust marketing network.

Grand Pharmaceutical’s SIR-Spheres® Y-90 Gains Early FDA Approval for New Cancer Treatment
Jul 7, 2025

Grand Pharmaceutical Group Limited announced that its associate company, Sirtex Medical Pty Ltd, received early FDA approval for a new indication of its SIR-Spheres® Y-90 resin microsphere injection, now approved for treating unresectable hepatocellular carcinoma (HCC). This approval highlights the company’s strong clinical registration capabilities and supports its strategy to expand its nuclear medicine offerings globally, reinforcing its leadership in the industry. The product, which has been widely adopted and recognized for its effectiveness, is expected to enhance the company’s market position and provide significant growth opportunities.

Grand Pharmaceutical Advances Ophthalmic Drug Development with CBT-001 Trial Milestone
Jun 4, 2025

Grand Pharmaceutical Group Limited announced the completion of patient enrollment for its Phase III clinical trial of CBT-001, an innovative ophthalmic drug for treating pterygium. This milestone is significant for the company’s strategic focus on ophthalmology, as CBT-001 has shown promising results in earlier trials and addresses a major unmet need in pterygium treatment. The company holds exclusive rights to produce and commercialize CBT-001 in several regions, enhancing its competitive edge in the market. Additionally, Grand Pharmaceutical is expanding its innovative product pipeline and strengthening its marketing network to support sustainable growth.

Grand Pharmaceutical’s Innovative Ophthalmic Product Gains Macao Approval
May 25, 2025

Grand Pharmaceutical Group Limited announced that its innovative ophthalmic product, GPN01768, has been approved for commercialization by the Pharmaceutical Administration Bureau of Macao, China. This approval is expected to pave the way for further approvals in the Guangdong-Hong Kong-Macao Greater Bay Area and Mainland China, addressing the urgent clinical need for effective treatment of Demodex blepharitis, a common ophthalmic disease. The company has made significant progress in its research and development pipeline, aiming to strengthen its position in the ophthalmology sector and expand its market presence with a series of innovative products.

Grand Pharmaceutical’s Chengdu Base to Boost Global Nuclear Medicine Strategy
May 18, 2025

Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Chengdu has obtained a Class A ‘Radiation Safety License’ and will soon commence operations. This development marks a significant milestone in the company’s strategy to become a global leader in nuclear medicine, enhancing its capabilities in isotope production and nuclear medicine preparation. The base, with an investment of over RMB 3 billion, features advanced technological breakthroughs and aims to set new safety benchmarks in the industry. It will support the company’s global strategy by providing a closed-loop system for R&D, production, and sales, and will contribute to the development of high-value nuclear medicine products, strengthening its position in the global market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025